Drugs / GSK1203486A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00706238 | Sep 2008 → Jan 2011 | melanoma | GlaxoSmithKline | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1203486A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00706238 ↗ |
| Known as | ASCI | “GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A” NCT00706238 ↗ |
| Route | Intramuscular | “IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.” NCT00706238 ↗ |